Endevica Bio
Columbia
About Endevica Bio
Endevica Bio create best-in-class peptide drug candidates with better safety and efficacy properties than other drugs in the same class. Endevica’s technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to perform with improved half-life, oral activity, and the ability to cross the blood-brain barrier.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2023)
- Website: endevicabio.com
- Phone: (573) 881-5080
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/endevica-bio-52545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.